Predicting the Response of Neoadjuvant Chemotherapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer With Axillary Lymph Node Metastasis by Multigene Assay.
Jun-Hee LeeJai Min RyuJee Hyun AhnSoo Youn ChoSe Kyung LeeJong Han YuByung Joo ChaeSeok-Jin NamJinil HanJeong Eon LeeSeok Won KimPublished in: Journal of breast cancer (2022)
We demonstrated that the BCT score predicts NACT responsiveness in HR+/HER2- BC with LN metastasis and might help determine whether NACT should be performed. Further studies are required to validate these results.
Keyphrases
- neoadjuvant chemotherapy
- epidermal growth factor receptor
- lymph node metastasis
- locally advanced
- squamous cell carcinoma
- tyrosine kinase
- lymph node
- sentinel lymph node
- advanced non small cell lung cancer
- endothelial cells
- papillary thyroid
- high throughput
- induced pluripotent stem cells
- pluripotent stem cells
- rectal cancer